July 24, 2012
(NYSE: LDR), a recognized leader in personal and environmental radiation monitoring, outsourced medical physics services and high quality medical consumable accessories, today announced that it appointed
to President of Landauer's Radiation Measurement segment effective immediately.
"Pete's previous professional experiences will make him a great addition to Landauer. His involvement with a very dynamic business in positron emission tomography (PET/CT) coupled with his leadership in delivering the first ever commercially viable, FDA approved Time-OF-Flight PET/CT System, is quite impressive. This was a market changing disruptive technology that changed the imaging landscape," said
, President and Chief Executive Officer of Landauer, Inc.
In this role, Mr. Cempellin will direct and lead the strategic and operating direction for the Dosimetry Products and Services Business. He will have responsibility for the firm's manufacturing operations, technical laboratory services and international channel partners within the corporation's radiation measurement business segment.
Prior to Landauer, Mr. Cempellin served as President and CEO of CAE Healthcare Inc., a provider of simulation training products including surgical, patient, and ultrasound imaging simulators addressing the educational needs of surgeons, gastroenterologists, cardiologists and intensivists.
Before joining CAE Healthcare, Mr. Cempellin held a variety of executive management positions including Vice President and General Manager at Analogic Corporation, a manufacturer of diagnostic computed tomography (CT) systems and image guided radiation therapy systems (IG-IMRT) and also served as General Manager of Philips Healthcare's Nuclear Medicine Business including PET/CT and molecular imaging systems. Under Mr. Cempellin, Philips Healthcare created the world's first Time-of-Flight PET/CT system, a breakthrough in medical imaging diagnostics and also initiated the world's first whole body PET/MR imaging system.
"Landauer is a world leader in radiation science and services, and I am delighted to join such a dynamic, innovative company," said Mr. Cempellin. "Given the company's strong position in occupational and patient radiation monitoring and services, I believe there are extraordinary opportunities to grow and build shareholder value. I look forward to working closely with Landauer employees, as well as customers, shareholders and business partners."